ACAD
ACADIA PHARMACEUTICALS INCPrice
Daily candles with volume. Callouts mark insider and congressional trades, rating changes, 13F stakes, reports, catalysts, court and regulator actions, Reddit spikes and short-interest jumps. Hover one for the details (tap on phones).
- Feb 25 ▲ Acadia Pharmaceuticals reported strong fourth quarter and full year…
- Mar 25 to Mar 26 ▼ 2 days of insider sells: $533.5K by 4 insiders, avg $21.50
- Apr 7 ▼ 2 insiders sell $83.0K at $22.20
- May 4 ▼ 2 insiders sell $105.4K at $21.79
- May 26 ▼ 1 insider sell $114.4K at $21.18
- Jun 26 ▼ 1 insider sell $297.9K at $26.08
- Jul 30 to Aug 6 ▼ 3 days of insider sells: $1.0M by 2 insiders, avg $27.79
- Sep 24 ▲ Acadia Pharmaceuticals announced Phase 3-enabling topline results fr…
- Oct 13 ▼ UBS downgrades
- Oct 30 ▼ 1 insider sell $69.3K at $20.88
- Nov 4 ▲ Earnings: ACAD Q3 2026 Earnings: EPS $0.31 (+54.8% vs est)
- Nov 4 ▲ Acadia Pharmaceuticals reported Q3 2026 GAAP total revenues of $342M…
Signal stack
Where each data set points today.
- InsidersBEARISH
5 insiders sold $2.2M.
- InstitutionsMIXED
Q2 2026: 31 added (0 new), 24 trimmed or exited.
- AnalystsBULLISH
20 of 27 rate it Buy or better. Median target $33.00 (+77%).
- Short sellersSTEADY
Short interest −8.5% to 8.32M shares. 5.9 days to cover, ≈4.8% of shares.
- TrendDOWNTREND
14% below its 50-day average.
Who's buying
13F· Q2 2026| Fund | Move | Value |
|---|---|---|
| GOLDMAN SACHS GROUP INC | ADD | $65.3M |
| Qube Research & Technologies Ltd | DOUBLED | $61.9M |
| CITADEL ADVISORS LLC | DOUBLED | $55.2M |
| ARROWSTREET CAPITAL, LIMITED PARTNERSHIP | ADD | $49.8M |
| MARSHALL WACE, LLP | DOUBLED | $44.7M |
| D. E. Shaw & Co., Inc. | DOUBLED | $43.0M |
| Nuveen, LLC | ADD | $34.1M |
| RENAISSANCE TECHNOLOGIES LLC | TRIM | $32.4M |
Quarterly 13F filings are due 45 days after each quarter ends.
The Street
27 analystsPrice is inside the target range. Median implies +77%.Targets as of Nov 16, 2026.
| Date | Firm | Rating |
|---|---|---|
| Nov 13, 2026 | Morgan Stanley MAINTAIN | Equal-Weight |
| Nov 6, 2026 | Canaccord Genuity MAINTAIN | Buy |
| Nov 5, 2026 | RBC Capital MAINTAIN | Outperform |
| Oct 19, 2026 | Needham REITERATE | Buy |
| Oct 13, 2026 | UBS DOWNGRADE | Neutral |
| Oct 8, 2026 | RBC Capital MAINTAIN | Outperform |
Insider ledger
Form 4| Insider | Type | Value |
|---|---|---|
Schneyer Mark C. EVP, CHIEF FINANCIAL OFFICER Oct 30, 2026 | SELL | $69.3K |
Schneyer Mark C. EVP, CHIEF FINANCIAL OFFICER Oct 15, 2026 | AWARD | 6,815 sh |
Schneyer Mark C. EVP, CHIEF FINANCIAL OFFICER Aug 6, 2026 | EXERCISE | $255.0K |
Schneyer Mark C. EVP, CHIEF FINANCIAL OFFICER Aug 6, 2026 | SELL | $145.0K |
Schneyer Mark C. EVP, CHIEF FINANCIAL OFFICER Aug 6, 2026 | SELL | $272.6K |
Schneyer Mark C. EVP, CHIEF FINANCIAL OFFICER Aug 5, 2026 | EXERCISE | $104.3K |
Schneyer Mark C. EVP, CHIEF FINANCIAL OFFICER Aug 5, 2026 | SELL | $169.6K |
Thompson Elizabeth H.Z. EVP, Head of Research & Dev Jul 30, 2026 | SELL | $431.4K |
Earnings setup
EstimatesRevision history: 🔒 Fresh data, subscribers only
| Period | EPS est. | Range | 30D rev. | Revenue |
|---|---|---|---|---|
| Current Q | 🔒 Fresh data, subscribers only | |||
| Next Q | 🔒 Fresh data, subscribers only | |||
| Current FY | 🔒 Fresh data, subscribers only | |||
| Next FY | 🔒 Fresh data, subscribers only | |||
Washington
Short side
FINRA· Oct 30, 2026SecBot reports
14 filings · 3 bullish · 2 bearish · 1 mixed · 8 neutral- NEUTRAL SC 13GNov 10, 2026
State Street Corporation filed a Schedule 13G disclosing a 4.4% passive stake in Acadia…
State Street's passive stake increase is routine for a large index fund manager and does not signal activist intent. Monitor the next 13F filing for any material changes in institutional…
- BULLISH 8-KNov 4, 2026
Acadia Pharmaceuticals reported Q3 2026 GAAP total revenues of $342M, up 22% YoY on a non-GAAP…
The strong DAYBUE growth and raised guidance confirm commercial momentum, but the decline in net income and elevated SG&A warrant monitoring. The upcoming Phase 2 readouts for ACP-211 and…
- NEUTRAL INST-CLUSTERNov 3, 2026
Five asset managers increased their ACAD positions in Q3 2026, with two funds more than doubling…
The cluster is small in dollar terms ($6.4M net vs. $3.6B market cap) and lacks insider corroboration. The 45-day reporting lag means these positions may already be unwound. Monitor next 13F filing…
- NEUTRAL 8-KOct 23, 2026
Acadia Pharmaceuticals filed an 8-K confirming the departure of Elizabeth H.Z. Thompson, Ph.D…
Monitor the next 8-K for the naming of a new Head of R&D appointment. The transition was pre-announced months ago and is not a surprise, no immediate trading catalyst.
All ACAD filing & press-release reports (14)
- SC 13G reportNov 10, 2026
- 8-K reportNov 4, 2026
- INST-CLUSTER reportNov 3, 2026
- 8-K reportOct 23, 2026
- 8-K reportSep 24, 2026
- 8-K reportSep 11, 2026
- INST-CLUSTER reportAug 16, 2026
- CLUSTER reportAug 7, 2026
- INST-CLUSTER reportJun 11, 2026
- 8-K reportMay 6, 2026
- CLUSTER reportMay 4, 2026
- CLUSTER reportMar 25, 2026
- 8-K reportMar 5, 2026
- 8-K reportFeb 25, 2026